|
CAP
|
HAP (excluding VAP)
|
|---|
|
Baseline risk factor
|
Ceftobiprole
|
Ceftriaxone ± linezolid
|
Baseline risk factor
|
Ceftobiprole
|
Ceftazidime plus linezolid
|
|---|
|
Any risk factor
|
193
|
205
|
Any risk factor
|
169
|
138
|
|
PORT ≥ III
|
126
|
117
|
APACHE score ≥ 15
|
67
|
59
|
|
PORT ≥ IV
|
51
|
58
|
>10 comorbidities
|
63
|
61
|
|
Sepsis
|
123
|
135
|
Mechanical ventilationa
|
38
|
37
|
|
Bacteraemiab
|
7
|
14
|
Bacteraemiab
|
15
|
11
|
|
Age ≥ 75 years
|
39
|
50
|
Age ≥ 75 years
|
59
|
54
|
|
COPD
|
51
|
59
|
COPD
|
55
|
39
|
|
ICU
|
25
|
26
|
ICU
|
73
|
59
|
- aMechanical ventilation at baseline or at any point during the study
- bFurther analyses were not conducted in the bacteraemia group as the number of patients in both treatment arms was below 20
- APACHE Acute Physiology and Chronic Health Evaluation, CAP community-acquired pneumonia, CE clinically evaluable, COPD chronic obstructive pulmonary disease, HAP hospital-acquired pneumonia, ICU intensive care unit, PORT Patient Outcome Research Team, VAP ventilator-associated pneumonia
